Ascentifi
Overview
Ascentifi is a venture capital investment firm based in Galway, Ireland. The firm prefers to invest in companies operating in the medtech, health tech, and digital health sectors. Ascentifi provides investment round accessibility to individual investors on a case-by-case basis. Ascentifi finds innovative, investor ready, MedTech companies, then presents each opportunity to the investors who have registered with us to be notified about these opportunities. The decision to invest lies with the individual investor. This case by case approach allows each investor to curate their own unique portfolio that aligns with their specific interests & risk appetites.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Tympany Medical | Nov 2021 | Seed | Co-investor |
| Vertigenius | Apr 2026 | VC Round | Co-investor |
| CroíValve | Jun 2026 | Series B | Co-investor |
| X-Bolt Orthopaedics | Oct 2023 | Series A | Co-investor |
| Bluedrop Medical | Mar 2023 | Series A | Co-investor |
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Ascentifi based?
Ascentifi is headquartered in Galway.
When was Ascentifi founded?
Ascentifi was founded in 2020.
How many portfolio companies does Ascentifi have?
Ascentifi has 5 portfolio companies in Caplight's dataset.
What are some companies in Ascentifi's portfolio?
Portfolio companies visible on Caplight include Tympany Medical, Vertigenius, CroíValve, X-Bolt Orthopaedics, Bluedrop Medical.
What was Ascentifi's most recent investment shown here?
Ascentifi's most recent investment in this portfolio sample was in CroíValve in 2026.
What sectors does Ascentifi focus on?
Ascentifi focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Frontier & Industrial Tech.
What company stages does Ascentifi focus on?
Ascentifi typically invests at the Early stage.
What is Ascentifi's AUM?
Ascentifi's assets under management are estimated between $0.0 and $50.0M.